| Date Filed | Type | Description |
| 10/05/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 10/02/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/21/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/14/2023 |
8-K
| Quarterly results |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 06/29/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 06/29/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/28/2023 |
4
| Swirsky Douglas J (Director) has filed a Form 4 on Cellectar Biosciences, Inc.|
Txns:
| Granted 37,500 options to buy
@ $1.85, valued at
$69.4k
|
|
| 06/28/2023 |
4
| NEIS JOHN (Director) has filed a Form 4 on Cellectar Biosciences, Inc.|
Txns:
| Granted 25,000 options to buy
@ $1.85, valued at
$46.3k
|
|
| 06/28/2023 |
4
| Loren Stefan (Director) has filed a Form 4 on Cellectar Biosciences, Inc.|
Txns:
| Granted 25,000 options to buy
@ $1.85, valued at
$46.3k
|
|
| 06/28/2023 |
4
| DRISCOLL FREDERICK W (Director) has filed a Form 4 on Cellectar Biosciences, Inc.|
Txns:
| Granted 25,000 options to buy
@ $1.85, valued at
$46.3k
|
|
| 06/28/2023 |
4
| Chanan-Khan Asher (Director) has filed a Form 4 on Cellectar Biosciences, Inc.|
Txns:
| Granted 25,000 options to buy
@ $1.85, valued at
$46.3k
|
|
| 05/04/2023 |
8-K
| Quarterly results |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/16/2023 |
4
| Shustov Andrei (Senior Vice President, Medical) has filed a Form 4 on Cellectar Biosciences, Inc.|
Txns:
| Granted 100,000 options to buy
@ $1.67, valued at
$167k
|
|
| 03/16/2023 |
3
| Shustov Andrei (Senior Vice President, Medical) has filed a Form 3 on Cellectar Biosciences, Inc. |
| 03/16/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 03/09/2023 |
8-K
| Quarterly results |
| 03/09/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/18/2023 |
4
| Longcor Jarrod (COO) has filed a Form 4 on Cellectar Biosciences, Inc.|
Txns:
| Granted 144,000 options to buy
@ $1.68, valued at
$241.9k
|
|
| 01/18/2023 |
4
| CARUSO JAMES V (President and CEO) has filed a Form 4 on Cellectar Biosciences, Inc.|
Txns:
| Granted 261,000 options to buy
@ $1.68, valued at
$438.5k
|
|
| 01/18/2023 |
4
| Kolean Chad J (CFO) has filed a Form 4 on Cellectar Biosciences, Inc.|
Txns:
| Granted 104,000 options to buy
@ $1.68, valued at
$174.7k
|
|
| 01/04/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 12/15/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/15/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 12/05/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 12/05/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 12/02/2022 |
8-K
| Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financi... |
| 11/23/2022 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 11/03/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/03/2022 |
8-K
| Quarterly results |
| 11/02/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
|